Download Image
    
Share
  
Post
Lanadelumab for COVID-19
1 study with 55 patients
Hospital Icon Control
Hospital Icon Lanadelumab Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Lanadelumab studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -7% Mortality -7% RCTs -7% Late -7% Favorslanadelumab Favorscontrol
Apr 7
2022
 Amgen, NCT04590586 Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
7% higher mortality (p=1), 10% greater improvement (p=0.79), 24% higher hospital discharge (p=0.57), and 9% worse recovery (p=1). RCT 55 hospitalized patients showing no significant difference with lanadelumab treatment.